Instem’s technology plays a critical role in helping scientists manage and document preclinical studies, including monitoring dosing, side effects and adverse reactions before generating regulatory submissions for bodies such as the FDA. Like many organisations with deeply embedded, business-critical platforms, Instem recognised an opportunity to modernise faster and more efficiently: the need to modernise was obvious, but the economics of doing it the old way were hard to defend. “We’d looked at modernising technology before but using traditional engineering approaches it was going to be extremely expensive and take a long time.” Mick Davison, SVP of Engineering at Instem. The partnership extends beyond the modernisation – Instem sees the programme as an opportunity to accelerate its wider AI transformation strategy, combining its own rapidly evolving capabilities with Godel’s experience of deploying agentic AI into production. “This is exactly the kind of transformation many businesses are now facing – organisations aren’t just modernising technology anymore, they’re rethinking how business processes operate and workflows are built.” Joe Wolski, CTO at Godel.